Age: 69.0
Sex: F
Vaccine: COVID19
Symptoms: Immunisation, Nausea, Pain, Photophobia, Pyrexia
Clinical narrative: severe headache; Pain, swelling and redness at injection site; Pain, swelling and redness at injection site; Pain, swelling and redness at injection site; Pain, swelling and redness at injection site; tiredness; weakness; sensitive to light; pain at location of a sinus headache; pain at location of a sinus headache; dizzy and nauseated when sitting or standing; dizzy and nauseated when sitting or standing; chills; Fever 99.8; lose of appetite; vomited; sweating; not steady on my feet; slept for over 12 hours; Booster; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 69 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), intramuscular, administered in arm left, administration date 05Jan2022 10:00 (Lot number: FL3197) at the age of 69 years as dose 3 (booster) , single for covid-19 immunisation. Relevant medical history included: "Breast cancer survivor" (unspecified if ongoing). There were no concomitant medications. Past drug history included: Known allergies: aspirin, reaction(s): "Known allergies: aspirin". Vaccination history included: Bnt162b2 (Dose Number: 2, Batch/Lot No: EP6955, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 06Apr2021, when the patient was 68 years old, for Covid-19 immunization; Bnt162b2 (Dose Number: 1, Batch/Lot No: EP6955, Location of injection: Arm Left, Route of Administration: Intramuscular), administration date: 18Mar2021, when the patient was 68 years old, for COVID-19 immunization. The following information was reported: HEADACHE (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "severe headache"; IMMUNISATION (non-serious) with onset 05Jan2022 10:00, outcome "unknown", described as "Booster"; VACCINATION SITE PAIN (non-serious), VACCINATION SITE SWELLING (non-serious), ERYTHEMA (non-serious), VACCINATION SITE REACTION (non-serious) all with onset 06Jan2022 07:00, outcome "recovering" and all described as "Pain, swelling and redness at injection site"; FATIGUE (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "tiredness"; ASTHENIA (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "weakness"; PHOTOPHOBIA (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "sensitive to light"; PAIN (non-serious), SINUS HEADACHE (non-serious) all with onset 06Jan2022 07:00, outcome "recovering" and all described as "pain at location of a sinus headache"; DIZZINESS POSTURAL (non-serious), NAUSEA (non-serious) all with onset 06Jan2022 07:00, outcome "recovering" and all described as "dizzy and nauseated when sitting or standing"; CHILLS (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "chills"; PYREXIA (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "Fever 99.8"; DECREASED APPETITE (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "lose of appetite"; VOMITING (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "vomited"; HYPERHIDROSIS (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "sweating"; GAIT DISTURBANCE (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "not steady on my feet"; SOMNOLENCE (non-serious) with onset 06Jan2022 07:00, outcome "recovering", described as "slept for over 12 hours". The patient underwent the following laboratory tests and procedures: body temperature: 96, notes: Fever 99.8 usually temperature is 96; 99.8, notes: Fever 99.8 usually temperature is 96. Therapeutic measures were not taken as a result of headache, vaccination site pain, vaccination site swelling, erythema, vaccination site reaction, fatigue, asthenia, photophobia, pain, sinus headache, dizziness postural, nausea, chills, pyrexia, decreased appetite, vomiting, hyperhidrosis, gait disturbance, somnolence.  No follow-up attempts are possible. No further information is expected.